Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease

Rahima A. Bhanji, Praveena Narayanan, Michael R. Moynagh, Naoki M Takahashi, Mounika Angirekula, Cassie Kennedy, Kristin C. Mara, Ross A. Dierkhising, Kymberly D. Watt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sarcopenia and frailty are commonly encountered in patients with end-stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait-list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated. We aim to ascertain the change in their prevalence over time on the wait list and determine their impact on hospitalization, delisting, and wait-list survival, specifically for patients with nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD). Adult patients who were evaluated for their first liver transplant from 2014 to 2016 with a primary diagnosis of NASH (n = 136) or ALD (n = 129) were included. Computed tomography scans were used to determine the presence of sarcopenia and myosteatosis. Frailty was diagnosed using the Rockwood frailty index. Patients with NASH had a significantly lower prevalence of sarcopenia (22% versus 47%; P < 0.001) but a significantly higher prevalence of frailty (49% versus 34%; P = 0.03) when compared with patients with ALD at the time of listing. In patients with NASH, sarcopenia was not associated with adverse events, but a higher frailty score was associated with an increased length of hospitalization (P = 0.05) and an increased risk of delisting (P = 0.02). In patients with ALD, univariate analysis showed the presence of sarcopenia was associated with an increased risk of delisting (P = 0.01). In conclusion, sarcopenia and frailty occur with differing prevalence with variable impact on outcomes in wait-listed patients with NASH and ALD.

Original languageEnglish (US)
Pages (from-to)14-24
Number of pages11
JournalLiver Transplantation
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Sarcopenia
Alcoholic Liver Diseases
Hospitalization
Non-alcoholic Fatty Liver Disease
End Stage Liver Disease
Tomography
Transplants

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Bhanji, R. A., Narayanan, P., Moynagh, M. R., Takahashi, N. M., Angirekula, M., Kennedy, C., ... Watt, K. D. (2019). Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. Liver Transplantation, 25(1), 14-24. https://doi.org/10.1002/lt.25346

Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. / Bhanji, Rahima A.; Narayanan, Praveena; Moynagh, Michael R.; Takahashi, Naoki M; Angirekula, Mounika; Kennedy, Cassie; Mara, Kristin C.; Dierkhising, Ross A.; Watt, Kymberly D.

In: Liver Transplantation, Vol. 25, No. 1, 01.01.2019, p. 14-24.

Research output: Contribution to journalArticle

Bhanji, RA, Narayanan, P, Moynagh, MR, Takahashi, NM, Angirekula, M, Kennedy, C, Mara, KC, Dierkhising, RA & Watt, KD 2019, 'Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease', Liver Transplantation, vol. 25, no. 1, pp. 14-24. https://doi.org/10.1002/lt.25346
Bhanji, Rahima A. ; Narayanan, Praveena ; Moynagh, Michael R. ; Takahashi, Naoki M ; Angirekula, Mounika ; Kennedy, Cassie ; Mara, Kristin C. ; Dierkhising, Ross A. ; Watt, Kymberly D. / Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. In: Liver Transplantation. 2019 ; Vol. 25, No. 1. pp. 14-24.
@article{c9abe0513a084a8d950a4c59a7165594,
title = "Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease",
abstract = "Sarcopenia and frailty are commonly encountered in patients with end-stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait-list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated. We aim to ascertain the change in their prevalence over time on the wait list and determine their impact on hospitalization, delisting, and wait-list survival, specifically for patients with nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD). Adult patients who were evaluated for their first liver transplant from 2014 to 2016 with a primary diagnosis of NASH (n = 136) or ALD (n = 129) were included. Computed tomography scans were used to determine the presence of sarcopenia and myosteatosis. Frailty was diagnosed using the Rockwood frailty index. Patients with NASH had a significantly lower prevalence of sarcopenia (22{\%} versus 47{\%}; P < 0.001) but a significantly higher prevalence of frailty (49{\%} versus 34{\%}; P = 0.03) when compared with patients with ALD at the time of listing. In patients with NASH, sarcopenia was not associated with adverse events, but a higher frailty score was associated with an increased length of hospitalization (P = 0.05) and an increased risk of delisting (P = 0.02). In patients with ALD, univariate analysis showed the presence of sarcopenia was associated with an increased risk of delisting (P = 0.01). In conclusion, sarcopenia and frailty occur with differing prevalence with variable impact on outcomes in wait-listed patients with NASH and ALD.",
author = "Bhanji, {Rahima A.} and Praveena Narayanan and Moynagh, {Michael R.} and Takahashi, {Naoki M} and Mounika Angirekula and Cassie Kennedy and Mara, {Kristin C.} and Dierkhising, {Ross A.} and Watt, {Kymberly D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/lt.25346",
language = "English (US)",
volume = "25",
pages = "14--24",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease

AU - Bhanji, Rahima A.

AU - Narayanan, Praveena

AU - Moynagh, Michael R.

AU - Takahashi, Naoki M

AU - Angirekula, Mounika

AU - Kennedy, Cassie

AU - Mara, Kristin C.

AU - Dierkhising, Ross A.

AU - Watt, Kymberly D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Sarcopenia and frailty are commonly encountered in patients with end-stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait-list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated. We aim to ascertain the change in their prevalence over time on the wait list and determine their impact on hospitalization, delisting, and wait-list survival, specifically for patients with nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD). Adult patients who were evaluated for their first liver transplant from 2014 to 2016 with a primary diagnosis of NASH (n = 136) or ALD (n = 129) were included. Computed tomography scans were used to determine the presence of sarcopenia and myosteatosis. Frailty was diagnosed using the Rockwood frailty index. Patients with NASH had a significantly lower prevalence of sarcopenia (22% versus 47%; P < 0.001) but a significantly higher prevalence of frailty (49% versus 34%; P = 0.03) when compared with patients with ALD at the time of listing. In patients with NASH, sarcopenia was not associated with adverse events, but a higher frailty score was associated with an increased length of hospitalization (P = 0.05) and an increased risk of delisting (P = 0.02). In patients with ALD, univariate analysis showed the presence of sarcopenia was associated with an increased risk of delisting (P = 0.01). In conclusion, sarcopenia and frailty occur with differing prevalence with variable impact on outcomes in wait-listed patients with NASH and ALD.

AB - Sarcopenia and frailty are commonly encountered in patients with end-stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait-list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated. We aim to ascertain the change in their prevalence over time on the wait list and determine their impact on hospitalization, delisting, and wait-list survival, specifically for patients with nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD). Adult patients who were evaluated for their first liver transplant from 2014 to 2016 with a primary diagnosis of NASH (n = 136) or ALD (n = 129) were included. Computed tomography scans were used to determine the presence of sarcopenia and myosteatosis. Frailty was diagnosed using the Rockwood frailty index. Patients with NASH had a significantly lower prevalence of sarcopenia (22% versus 47%; P < 0.001) but a significantly higher prevalence of frailty (49% versus 34%; P = 0.03) when compared with patients with ALD at the time of listing. In patients with NASH, sarcopenia was not associated with adverse events, but a higher frailty score was associated with an increased length of hospitalization (P = 0.05) and an increased risk of delisting (P = 0.02). In patients with ALD, univariate analysis showed the presence of sarcopenia was associated with an increased risk of delisting (P = 0.01). In conclusion, sarcopenia and frailty occur with differing prevalence with variable impact on outcomes in wait-listed patients with NASH and ALD.

UR - http://www.scopus.com/inward/record.url?scp=85059500677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059500677&partnerID=8YFLogxK

U2 - 10.1002/lt.25346

DO - 10.1002/lt.25346

M3 - Article

C2 - 30257063

AN - SCOPUS:85059500677

VL - 25

SP - 14

EP - 24

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 1

ER -